thought call
would character jnj result solid strength pharma
seem one-tim less durabl franchis remicad see biosimilar
pressur although maintain volum favor impact
rebat adjust major payer zytiga unusu strong upsid
third consecut upsid quarter loe impact pharma growth
next year wont off-set erleada overal encourag newer
product cycl darzalex erleada tremfya uptravi etc offset remicad
zytiga invokana could continu curtail pharma growth deceler
oper segment growth beyond pharma vision
surgeri help medic devic segment orthopaed struggl
expect vision remain strong expect much happen ortho
least later year aid new launch final consum help
beauti howev babi like continu under-perform plan restag
divis quarter strong point continu believ
could see pharma growth trough interim slower medic devic util
lower consum growth support balanc risk/reward profil given
maintain ew rate lower pt
question remain turnaround babi consum ortho
devic expect detail upcom busi review day believ
challeng remain babi consum ortho sell day
impact ortho modestli think broader headwind face segment
includ price pressur could difficult overcom babi care slate
restag await clariti becom comfort
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight think outlook intact
recent success pharmaceut broader
move away defens stock less like
result share continu outperform
remicad biosimilar moder pipelin
potenti slow medic devic util full
consum stapl valuat make
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commer success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
given recent trend commentari updat model notabl
increas revenu see revenu
oper margin improv slightli driven primarili
slightli slower increas sell market expens given chang see
ep figur detail
price target reflect blend averag compar
analysi suggest valu per share base appli current year price-to-earnings
multipl forward year earn sum-of-the-part analysi use pharma med tech
consum peer forward year price-to-earnings multipl suggest per share dcf
analysi assum wacc termin growth rate
conserv growth trajectori long-term indic intrins valu
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
